Antibe Therapeutics Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was CAD 19.48 million compared to CAD 25.06 million a year ago. Basic loss per share was CAD 0.37 compared to CAD 0.5 a year ago.
Antibe Therapeutics Inc.
Equities
ATE
CA0370255097
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+18.15% | 124B | |
+18.02% | 112B | |
-12.75% | 22.22B | |
+5.07% | 22.94B | |
-39.94% | 16.87B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |